Side-effect free RNA therapeutics active only in diseased cells

SRTD biotech secures seed financing

18-Nov-2024 - Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient ...

Generative AI antibody design platform

Antiverse raises £3.5M

21-Oct-2024 - Antiverse, a techbio company designing antibodies for challenging targets, announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many ...

ImmunOs Therapeutics raises $11 million and further strengthens investor base

“ImmunOs Therapeutics has a very innovative approach to target myeloid checkpoints which are potentially the next major breakthrough in immuno-oncology”

24-Sep-2024 - ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a Series C financing round of $11 million. The ...

Efficiency boost for drug discovery

Insilico Medicine and Inimmune achieved collaboration to revolutionize immunotherapy with AI-driven drug discovery

12-Sep-2024 - Insilico Medicine announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico's proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation ...

LMU research transfer: several start-ups attract 7-figure investments

In successful funding rounds, three LMU spin-offs have brought in investments worth millions.

25-Jun-2024 - Tubulis, Smart Reporting, and Eisbach Bio have successfully attracted new investor funding. The new capital will enable the companies, for example, to expand their research and development activities. Tubulis and Eisbach develop new therapeutic approaches and active agents for cancer treatment, ...

Biotechnology start-up using AI to translate nature into new medicines

Enveda Biosciences announces $55M in new funding to accelerate platform and advance multiple candidates to clinical trials

19-Jun-2024 - Enveda Biosciences announced a new financing round of $55 million to add to its $119 million combined Series B and B1. New investors Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy participated in the round alongside existing investors Kinnevik, True Ventures, FPV, ...

Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs

17-Jun-2024 - Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension round was led by new investor Thuja Capital, and as part of the financing, Evan ...

Game changer in fighting cancer: BioCopy expands corporate portfolio with acquisition of start-up Perspix Biotech

"BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint"

11-Apr-2024 - BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and ...

Tubulis closes upsized €128 million Series B2

"This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space"

18-Mar-2024 - Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led byEQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation from new US-based funds, Frazier Life ...

Insamo launches with $12m funding to develop best-in-class membrane-permeable macrocyclic peptides

"Turn-key" solution from Insamo to revolutionise drug discovery

26-Feb-2024 - Insamo, a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides, announced $12 million in seed capital from Playground Global, venBio, and MRL Ventures Fund (MRLV). MRLV is a corporate venture arm of Merck & Co., Inc which invests in ...